It’s pretty unlikely to scroll on TikTok and not see or hear anything about Ozempic these days. These weight loss medications have gone from professional use to mainstream quite quickly over the past couple years. It’s also quite possible and likely that one of your favorite celebrities has also dipped their toes in this weight loss epidemic. I mean, we’ve all seen the now-viral photo of Demi Moore with her “toned arms” at the Cannes Film Festival 2026. These medications, like Ozempic, Wegovy, and Mounjaro, might be things you just casually hear now in podcasts and interviews.
This change in consumer behavior around weight loss drugs has pushed research scientists into exploring other avenues that don’t just target hormones like appetite regulation but multiple biological pathways. The GLP-1 drugs may be the most popular peptides at the moment but are not the end of it. There are many more peptides and therapies being developed at present.
One such peptide that is talked about in the same breath as other weight loss drugs is Cagrilintide, also called CAG. So, Cagrilintide is not a GLP-1 receptor agonist like the other weight loss peptides. It’s more of a long-acting analog of amylin. Amylin occurs naturally in the body and helps regulate an individual’s appetite after meals.
CAG is a promising avenue in obesity research and is being studied with GLP-1 drugs and alone to better understand its efficacy. We take a closer look at it and understand the uses, benefits, and consequences of CAG in this article.
What is Cagrilintide?
Cagrilintide is a long-acting synthetic analogue of amylin. Amylin is a hormone that the pancreas produces along with insulin when an individual consumes food. We are all aware that insulin is important in regulating our blood sugar levels, and if our bodies don’t respond to insulin, then we can experience spikes in our blood sugar. Well, amylin is another hormone that plays a complementary role to insulin and helps in controlling appetite. It also signals to the brain when the body has eaten enough food.
The issue is that amylin can get broken down too quickly by the body. That is where the CAG peptide enters the conversation. Cagrilintide has been developed to mimic the effects of amylin and stays active for a longer time in the body. The aim with this is to prolong the activity of this hormone and help individuals reap the benefits of a more controlled appetite.
CAG is a promising avenue in obesity research at present. The peptide is being studied as a potential treatment option for obesity and overweight problems. CAG has shown a promising lead when it has been studied with other GLP-1 agonists and also when it has been studied separately.
How does CAD work?
As we mentioned, CAD mimics the actions of amylin. CAD won’t necessarily work on your metabolism and increase its speed. What it will do is that it will affect your biological signals that make decisions about your hunger and how satisfied you feel after eating.
After you have eaten a meal, amylin communicates with particular brain areas that are involved in controlling appetite. CAG has been formulated to improve these signals that amylin sends and help people feel fuller sooner than they typically do and help them remain satisfied for a longer period of time.
Along with this, it also slows down the speed at which your stomach digests and empties out food. If food leaves the stomach at a gradual pace, that also helps a person stay full for a longer time. Most of us, guiltily, indulge in those snacking behaviors or midnight cravings. We all know they’re bad, but we do it anyway. We just can’t seem to stop sometimes. That is what CAG can help individuals out with.
Experts believe that individuals may not even have to calorie count or restrict their food intake too much since the combined effects of CAD can also naturally reduce their calorie intake. Since obesity is more than just someone’s lifestyle and is influenced by hormones as well, CAG seems like a beneficial treatment option since it targets an individual’s physiology rather than just relying on their willpower. Current research has also suggested that it can be paired with the other GLP-1 peptides already present in the market.
Potential uses of CAD
CAD is being studied for a number of potential applications in terms of obesity and an individual’s metabolic health.
Weight management is a primary aim of CAD in adults who are obese or overweight. Clinical trials have been done on the peptide, and the studies suggest that CAD may prove to be beneficial in helping individuals achieve their required weight loss aims if they combine it well with a low-calorie diet and exercise.
CAD also plays a role in appetite regulation, it’s basically one of its most important functions. CAD increases the feeling of fullness one may experience and reduces the hunger cravings they may have between their meals. This helps them reduce their calorie intake without emotionally feeling too deprived of food.
CAD’s potential in influencing an individual’s metabolic health is another area that’s been under investigation. Researchers are studying whether the regulation of appetite or weight loss can help bring about some improvements in a person’s blood sugar control or protect them from certain cardiovascular risks. There’s not yet been conclusive data on this. The research is still ongoing.
Another area where CAD can be used is alongside other GLP-1 receptor agonists like semaglutide. Products like Ozempic or Wegovy consist of semaglutide as well. Both of these medications do work through different hormonal pathways, but they can complement each other and help with better weight loss outcomes.
Side effects and Warnings of CAD
While CAD can be beneficial for obesity and weight loss, it still has side effects that an individual should be aware of.
The most common side effects you may experience with CAD are:
- Nausea
- Vomiting
- Diarrhea
- Constipation
- Reduced appetite
- Abdominal discomfort
These are some common side effects that have been reported as of yet. The research is still ongoing on this peptide.
Final Thoughts
CAD brings about a promising lead in the field of obesity research. Individuals no longer only have to rely on their willpower to reduce their cravings or their caloric intake. Compounds like amylin can help them on the inside.
While the research is still going, CAD can be part of a healthy and sustainable weight management journey if someone pairs it with a healthy diet and required exercise. Its potential to be paired with other GLP-1 medications is also potentially an interesting avenue that could really help the field of obesity research, since it’s such a growing concern among millions of Americans.
FAQs
1. What is CAD used for?
CAD is mainly used to manage obesity and trigger weight loss in individuals who are overweight or need to protect themselves against cardiovascular complications.
2. How does CAD work?
CAD targets your appetite regulation and feeling of fullness and satisfaction primarily. It does that by mimicking the amylin hormone.
3. Are Cagrilintide and GLP-1 the same?
No, not necessarily. Cagrilintide is an analog of amylin, while GLP-1 drugs mimic the GLP-1 hormone. They can work in great tandem with each other but are not the same.
4. What are common side effects of Cagrilintide?
The common side effects that have been reported as of yet are nausea, stomach discomfort, vomiting, diarrhea, or constipation. Trials have seen that these side effects are experienced more when the CAD treatment is started.
